Company / Debt per Share
UroGen Pharma Ltd. Debt per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$2.96
FY2025
5-year range
$0.00 / $4.34
FY2021-FY2025
Trend
-21.0%
vs FY2024
Sector context
#37 of 82
Health Care
What the data says
At $2.96, UroGen Pharma Ltd.'s debt per share ranks #46 of 82 in the Health Care sector. Debt per Share has declined for 3 consecutive years, from $4.34 in FY2022 to $2.96 in FY2025.
Based on SEC 10-K filings.
2.96 in FY2025 with a 3-year CAGR of -12.0%.
Improved from $4.26 to $2.96 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -12.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#46 of 82 in Health CareTop 55% of 82This company $2.96 Sector average $151.59
▼
-98.0% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s debt per share has declined for 3 consecutive years.
- In FY2025, debt per share decreased 21.0% year-over-year.
- Ranks #37 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.96 | -21.0% |
| FY2024 | $3.75 | -12.1% |
| FY2023 | $4.26 | -1.9% |
| FY2022 | $4.34 | - |
| FY2021 | $0.00 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026